text_1: Lysine histone demethylase inhibitor JIB 04 is inactive against KDM5A.
text_2: Thus, JIB-04, a novel inhibitor of Jumonji demethylases in vitro and in vivo, constitutes a unique potential therapeutic and research tool against cancer, and validates the use of unbiased cellular screens to discover chemical modulators with disease relevance.